Notably, increasing evidence proves that CMTM6, a regulator of PD-L1, can maintain the expression of PD-L1 and enhance the ability of PD-L1 expression in tumor cells to inhibit T cells (Burr et al., 2017; Mezzadra et al., 2017). The gene discussed is CMTM6; the disease is neoplasm.